Indications and contraindications of dental implants in medically compromised patients: update by Gómez de Diego, Rafael et al.
Med Oral Patol Oral Cir Bucal. 2014 Sep 1;19 (5):e483-9.                                                                                                                                     Dental implants in medically compromised patients
e483
Journal section: Medically compromised patients in Dentistry
Publication Types: Review
Indications and contraindications of dental implants in 
medically compromised patients: Update
Rafael Gómez-de Diego 1, María del Rocío Mang-de la Rosa 2, María-Jesús Romero-Pérez 3, Antonio Cutando-
Soriano 4, Antonio López-Valverde-Centeno 5
1 Department of Stomatology, University Rey Juan Carlos, Madrid, Spain
2 Department of Special Care patients, School of Dentistry, University of Granada, Spain
3 Department of Special Care patients, School of Dentistry, University of Granada, Granada, Spain
4 Special Care Professor, University of Granada, Department of Special Care Dentistry, School of Dentistry, University of Gra-
nada, Granada, Spain
5 Department of Surgery, School of Dentistry, Faculty of Medicine, University of Salamanca, Salamanca, Spain
Correspondence:
Departamento Cirugía
Universidad de Salamanca
Avda. Alfonso X El Sabio S/N
37007 Salamanca. España
anlopezvalverde@gmail.com
Received: 20/09/2013
Accepted: 29/09/2013
Abstract
The aim of this study was to review the current scientific literature in order to analyse the indications and contrain-
dications of dental implants in medically compromised patients. A reference research was carried out on PubMed 
using the key words “implant” AND (oral OR dental) AND (systemic disease OR medically compromised), in 
articles published between 1993 and 2013. The inclusion criteria were the following: clinical studies in which, 
at least, 10 patients were treated, consensus articles, reviewed articles and meta-analysis performed in humans 
treated with dental implants, and which included the disease diagnosis. A total of 64 articles were found, from 
which 16 met the inclusion criteria. 
Cardiac systemic diseases, diabetic endocrine pathologies or controlled metabolic disorders do not seem to be 
a total or partial contraindication to the placement of dental implants. Tobacco addiction, and head and neck 
radiotherapy are correlated to a higher loss of dental implants. Patients suffering from osteoporosis undergoing 
biphosphonates therapy show an increased risk of developing bone necrosis after an oral surgery, especially if the 
drugs are administered intravenously or they are associated to certain concomitant medication.
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Introduction
A medically compromised patient (MCP) can be de-
scribed, as the one who has a distinctive physical or 
mental feature regarding the people of the same age. In 
this sort of patients there is a higher risk of interactions 
between their disease and the implant surgery, imply-
ing a higher medical risk. This group need, therefore, 
to fill in a medical questionnaire and to undergo a pre-
vious exhaustive medical examination, which will help 
not only to determine the specific measures that must 
be adopted (1), but also to carry out the estimation of 
the patient’s risk. The system proposed by the Ameri-
can Society of Anesthesiologists in 1941, and the one 
adapted by McCarthy and Malamed (2,3) to the den-
tal patient  were used to define the patient’s risk. These 
classifications as well as the medical history allow us to 
identify the systemic disease and the success rate ex-
pected in the MCP that is going to be rehabilitated with 
dental implants. It seems like the medical control of the 
disease is more important than the disease itself. This 
evidences the need of carrying out personalized medi-
cal examinations (4). 
Medical advances have made possible the increase of the 
survival rate of certain types of medically compromised 
patients, increasing thus the prevalence of MCP who re-
quest the rehabilitation of their total or partially edentu-
lous maxillary bones with dental implants. This is due 
to the high success rate of this surgical technique and its 
benefits to the patients’ function and quality of life.
Among scientific literature there is an enormous varie-
ty of studies that analyse the most common systemic 
diseases presented by patients undergoing dental treat-
ment, correlating it with adequate and safe clinical 
practices and existing little information which associate 
these diseases with dental implants surgery. 
Objectives
The aim of this study is to thoroughly revise the current 
literature, in order to analyse the indications and con-
traindications of treating MCP with dental implants. 
Material and Methods
A reference research was carried out at the access por-
tal PubMed, using the keyword  “implant*AND (oral 
OR dental) AND (systemic disease OR medically com-
promised), limiting the research to articles published in 
dental journals between 1993 and 2013. Moreover, the 
articles should be written in English and the abstracts 
should also be published in that database. 
The inclusion criteria were the following: clinical stud-
ies in which, at least, 10 patients were treated, consensus 
articles, review articles and meta-analysis performed 
in humans treated with dental implants and includ-
ing the disease diagnosis. The following features were 
registered for each study: publication year, systemic 
disease, number of dental implants placed and their 
survival rate. The goal was to evaluate whether or not 
exists correlation between: head and neck radiotherapy 
treatment, intake of biphosphonates, systemic diseases 
including cardiac systemic diseases, diabetic endocrine 
pathologies, osteoporosis and tobacco consumption and 
the lack of osseointegration of the dental implants.
Results and Discussion
A total of 64 articles were found using the research strat-
egy described above and 18 of them met the inclusion cri-
teria. The latter followed an specific analysis (Table 1). 
The evidence level of implant failures in MCP is limited 
(5) due to the short number of controlled randomised 
studies. There are even retrospective studies, with 3 
years of follow up, in geriatric MCP (70 years and over), 
which conclude that controlled systemic diseases should 
not be considered as a risk factor for dental implants 
failure (p=0,484) subjected to prosthetic charge (6). 
The cardiac systemic disease (CSD) can endanger and 
reduce the amount of oxygen and nutrients in the osseous 
tissue, which may affect the osseointegration process of 
dental implants. Some authors (7,8) even point out the 
relative contraindication of placing dental implants in 
patients with certain CSD due to their higher risk of 
developing infective endocarditis. On the contrary, it 
does not seem to exist correlation between the lack of 
osseointegration of dental implants and patients with 
certain CSD, as concluded by Khadivi and cols in their 
retrospective case study of MCP (n=148) and healthy 
controlled patients (n=98). There were found 39 patients 
affected by a cardiac pathology (23,9%), registering a 
13% failure rate in these patients and a 12% failure rate 
in the control group (9). 
In none of the studies, except for one, radiotherapy was 
mentioned as a risk factor associated to the frequency of 
dental implants loss (10). The authors describe a sample 
of 1514 implants analysed in 700 patients, with a retro-
spective two-year follow-up. 
This kind of treatment involving ionizing radiation and 
when placed over the oral cavity, can be relevant in 
order to explain the association between radiotherapy 
and loss of dental implants. It has been suggested that 
therapy with hyperbaric oxygen could reduce the inci-
dence of loss of dental implants in irradiated patients. 
In a recent systematic review (11), the authors were only 
able to find a controlled and randomised study, in which 
dental implants where placed in a group of premedicat-
ed patients, compared to another study that used both 
premedication and hiperbaric therapy, obtaining a 85,2 
% survival rate in the first study and a 93,3% survival 
rate in the second one. This leads the authors to con-
clude that the use of hyperbaric treatment in patients 
undergoing implant treatment does not seem to provide 
significant benefits. 
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Author and year Type of study Number of 
implants
Survival rate (%) Contraindication 
evidence
Dios y cols; 2013 review - -
The disease control is 
more important than 
the disease itself. 
Lee y cols; 2011 retrospective 249 97,3 
Correlation between 
smoking and dental 
loss.  
Lee y cols; 2010 prospective - - No contraindication 
found in geriatric MCP 
Bornstein y cols; 
2009
review - -
MCP suffering DB 
registers higher implant 
loss. 
Michaeli y cols; 2009 review - -
MCP suffering DB 
present higher implant 
loss. 
Holahan y cols; 2008 retrospective 646 93,8 
Smoking increases    by 
2,6 the risk of implant 
loss. 
Sverzut y cols; 2008 review 1.628 96,6 
Smoking can not be 
considered as a risk 
factor 
Alsaadi y cols; 2008 retrospective 1.514 -
Radiotherapy in the 
head and neck region is 
associated to loss of 
implants 
Alsaadi y cols; 2008 prospective 720 98,1 
Correlation between 
DB type I, smoking 
and high failure rate 
Scully y cols; 2007 review - -
The disease's control is 
more important than 
the disease itself. 
Alsaadi y cols; 2007 retrospective 6.946 96,4 
Correlation between 
smoking, osteoporosis 
and a higher loss of 
implants. 
Hwang y Wang; 2007 review - - Controlled MCP show 
high survival rate 
Mombelly y Cionca; 
2006 review - -
Increased failure risk in 
patients suffering from 
DB
Beikler y Flemmig; 
2003
review - -
MCP with controlled 
DB type II must 
receive previous 
antibiotic prophylaxis.  
Khadivi y cols; 1999 retrospective - 87,0 
MCP with a CSD do 
not show a higher loss 
of implants 
Blanchaert; 1998 review - -
Correlation between 
osteoporosis and  
higher loss  
MCP: medically compromised patient 
DB: diabetes mellitus 
CSD: cardiac systemic disease 
Table 1. Data collected from the articles that met the inclusion criteria.
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Radiotherapy could be responsible in the reduction of 
the success rate of dental implants when it is adminis-
tered in doses exceeding 50 Gy, as it has already been 
proved for extraoral implants. To that effect, Verdon-
ck and cols performed a case-control study using the 
maxilla and mandible of six adult Göttingen minipigs. 
The maxilla and mandible of three minipigs received 
irradiation exposures at a total dose of 24 Gy and 120 
implants were placed with perioperative and postopera-
tive recordings for the implant stability quotient (ISQ) 
at 8, 16, and 24 weeks after the implant placement. ISQ 
values recorded immediately after implant placement 
showed no difference between irradiated and non-irra-
diated minipigs, but the repeated measurements at the 
four recording moments showed a decrease of ISQ va-
lues when compared with non-irradiated bone (12).
The consumption of tobacco seems to be a factor as-
sociated with the increase in the loss of dental implants; 
Wilson and Nunn established a failure rate 2.5 times 
higher in patients who smoke (13), and this rate has aug-
mented in recent studies (14,15) up to a 2.6 in smok-
ers as compared with non-smokers. These results seem 
contradictory with those found by Alsaadi and col in 
their two years retrospective study, as they concluded 
that the consumption of tobacco is not a decisive factor 
in the loss of dental implants (10), which is similar to 
the results found by Sverzut and col in their retrospec-
tive study (16). Among the studies reviewed specifically 
for this article, 4 of them associated the consumption of 
tobacco with the implant loss significantly, as opposed 
to 2 of them already mentioned( 8,17-19) (Table 2).
Author and year Sort of study Number of failures Conclusions 
Lee y cols; 2011 retrospective 5 Associated with dental loss 
Alsaadi y cols; 2008 retrospective ND No association 
Alsaadi y cols; 2008 prospective 14 association 
Sverzut y cols; 2008 retrospective 46 No association 
Alsaadi y cols; 2007 retrospective 250 association 
Hwang y Wang; 2007 review ND association 
ND: no data 
Table 2. Correlation between snuff consumption and loss of dental implants.
Metabolic changes produced by diabetes are associated 
with the synthesis of the osteoblastic matrix induced by 
insulin. The variation in the differentiation of osteoblas-
tic cells and hormones which regulate the calcium metab-
olism, produce, in the mineral bone tissue homeostasis, 
an alteration in the level of bone matrix required to pro-
duce mature osteocytes which boost the osseointegration 
of dental implants. Epidemiological case-control studies 
carried out in animals show a variation in the bone densi-
ty surrounding the implant in samples of non-controlled 
diabetic patients (20,21). Most studies reviewed confirm 
these experimental results. Morris and col. in their 3 year 
restrospective study, show a higher frequency of im-
plant failure in diabetic patients (7.8%) as compared with 
healthy patients (6.8%) (22). These data are confirmed in 
the thorough review of Mombelly and Cionca (23) or in 
a recent one carried out by Bornstein and col (7). The 
most recent publications arise different results in spite of 
insisting on the higher risk of failure in diabetic patiens 
(24). In that way, Alsaadi and col (10) analyzed seven sys-
temic diseases in a restrospective study with a large sam-
ple (n=700) and concluded that diabetic endocrine patho-
logy is not associated with a higher frequency of failure 
in dental implants, though the same author pointed out 
in another study carried out in the University of Leuven 
(16) with a smaller sample of patients (n=273) and twelve 
systemic diseases analyzed, that patients who suffer 
from diabetes type I have more tendency towards dental 
implant failure. These results are conflicting with those 
published by the same author in 2007 (20), when 6946 
dental implants were placed in 2004 patients with the loss 
of 252 implants; the analysis carried out about the early 
loss of implants points out just one patient who suffered 
from diabetes type I and the frequency of 4% in early 
implant failure (n=14) associated with diabetes type II. In 
the light of the results exposed, the total contraindication 
of placing dental implants in diabetic patients because of 
the higher frequency of failure in the osseointegration 
and risk of infection (24) proposed in the past, has been 
modified owing to the fact that the risk of augmenting the 
failure rate in controlled diabetic patients who have been 
placed dental implants is only relative when they have 
received an antibiotic prophylaxis protocol and aseptic 
techniques with chlorhexidine gluconate  0.12% (1,22).
Osteoporosis, metabolic disease which modifies the bone 
mass and density, is the most frequent bone disorder, 
which affects sponge bone mainly and is more common 
in postmenopausal women. It has been considered for a 
long time that this disease complicates the initial stabil-
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ity of dental implants because of the loss in the sponge 
bone mass (25). However, current publications show high 
survival rates, between 93.8 and 100% (17). A recent 
retrospective study analyzes 646 dental implants placed 
in 50 or more year old women (n=192), diagnosed with 
osteopenia or osteoporosis and who were tested their mi-
neral bone density, being the survival rate of the implants 
5 years later of 93.8%, which demonstrates the absence 
of an statistically significant association between this dis-
ease and the failure in implants (15).
It has also been observed an adequate percentage of con-
tact bone-implant in women who suffer from osteoporo-
sis through histomorphometry studies. In that way, Melo 
and col described a case report of a 68 year old postmen-
opausal woman who had a 62.51% contact bone-implant 
after 6 years of loading it (26). A recent case-control epi-
demiological study evaluated a sample of 21 patients, 7 of 
them were postmenopausal women suffering from oste-
oporosis and 14 did not show signs of this pathology. The 
percentage of bone-implant contact was of 46 in the first 
group as opposed to the 47.84% of the control group (27). 
Both articles concluded that osteoporosis may not be a 
contraindication for the placement of dental implants.
The bifosfonates (BF), drugs indicated in the prevention 
and treatment of illnesses associated to bony resorption 
(ederly osteoporosis , induced by corticoids, or Paget 
disease), bony metastasis of cancer from suckles and 
prostate, syndromes paraneoplásics (wicked hypercal-
cemia) and multiple myeloma. They can be used for via 
oral or intravenous.
The PMC in treatment with BF, especially those admi-
nistered for intravenous via, they present bigger inci-
dence of  risk of suffering osteonecrosis (OQN) (BCN, 
Bone Chemical Necrosis) at the maxillary to the sub-
jected being to oral surgical treatments (28). This way, 
Kasai and cols., they compare the failure of the dental 
implants  in two groups of women: prescribed with oral 
BF (n=11) (OBF, Oral Biphosphonates) in front of not 
prescribed (n=54), obtaining a rate of survival in you 
implant them of 86% in the cases in front of 95% of the 
controls (29). There are not unanimous consent, neither 
conclusive data in the attitude to take before the insert 
the dental implant in PMC in treatment  with oral BF, al-
though the most recent clinical studies  show a relation-
ship between the treatment with oral BF, use of dental 
implant, and  the frequency of success and the presence 
of OQN (Table 3) they seem to endorse the security of 
the technique in this type of PMC (30-37). By the other 
side, it is necessary to make the PMC tried with intrave-
nous BF of the drop periimplantitis incidence, but high 
risk of OQN . Risk that is increased if the case of PMC 
receiving treatment with ciclosporin, azathioprine or 
similar, corticoids or hormonal therapy, in this case its 
is  an absolute contraindication (38-40). 
Author and 
year 
OBF
treatment, 
in months 
Implants
(cases)
Implants
(control) 
Follow up 
in months 
Survival
(% cases) 
Survival (% 
control) 
OQN
Jeffcoat (2006) 36  102 108 36  100 99,2 0 
Fugazzotto y 
cols. (2007)   39 169 - 12-24  100 - 0 
Grant y cols.  
(2008)  37 468 1450 48  99,5 99 0 
Bell y Bell. 
(2008)  de 6 a 132 100 734 37  95 96,5 0 
Koka y cols. 
(2010)  48 121 166 - 99,1 98,1 0 
Shabestari y 
cols. (2010)  20,5  46 - - 100 - 0 
Zahid y cols. 
(2011)  41,1 51 610 26  94,1 97,7 0 
Memon y cols. 
(2012)  de 12 a 36 153 132 - 93,5 95,5 - 
OBF: Oral Bisphosphonates 
BCN: Bone Chemical Necrosis  
Table 3. Correlation between consumption of OBF, dental implants and BCN.
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Conclusions
The survival rate of dental implants placed in MCP who 
suffer from controlled systemic diseases or smoke, does 
not indicate a total or partial contraindication for the 
placement of dental implants, as the level of evidence 
associated with the implant loss is low, it seems to be 
a secure procedure which do not have to be considered 
risky, though there is not available information recorded 
in patients suffering from severe diseases. The consump-
tion of oral biphosphonates by patients who suffer from 
osteoporosis seems to be a partial contraindication for the 
treatment with dental implants and the patient must un-
derstand the necessity of a longer follow-up period so as 
to detect any sign of BCN. On the contrary, those patients 
who have been subjected to radiotherapy protocols in the 
head or neck region, with doses higher than 50Gy, seem 
to show lower levels of osseointegration throughout the 
time, being contraindicated their placement in those pa-
tients who have received a therapy with biphosphonates 
intravenously and when they are associated with hormo-
nal therapy, corticosteroids or immunosupressors.
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